A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Inclusion Criteria: 1. Subject must have relapsed or refractory disease. 2. Subject must have histologically documented diagnosis of non-hodgkin's lymphoma as defined by a B-cell neo-plasm in the World Health Organization (WHO) classification scheme except as noted in exclusion criteria. 3. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. 4. Subject has adequate bone marrow (independent of growth factor support per local laboratory reference range). 5. Subject has adequate coagulation, renal and hepatic function. Exclusion Criteria: 1. Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD), Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia (CLL), mantle cell leukemia (MCL), or small lymphocytic lymphoma (SLL). 2. Subject has undergone an allogeneic stem cell transplant. 3. Subject is receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV) (due to potential drug-drug interactions, as well as the potential for increased risk of opportunistic infections). 4. Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease within 6 months that in the opinion of the Investigator would adversely affect his/her participation in this study. 5. Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.